Arena Pharmaceuticals drops after CHMP issues recommendations The stock is down over 5.4% at time of writing, edging toward session lows. At the current price of $9.87, next support is at $9.47. Resistance is at the 10-day moving average, last at $10.03.
Arena says Teva files marketing authorization of Belviq in Israel Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.